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Abstract 
Background: Autism spectrum disorder (ASD) is a complex neurodevelopmental condition whose biological basis is 
yet to be elucidated. The Australian Autism Biobank (AAB) is an initiative of the Cooperative Research Centre for Living 
with Autism (Autism CRC) to establish an Australian resource of biospecimens, phenotypes and genomic data for 
research on autism.
Methods: Genome-wide single-nucleotide polymorphism genotypes were available for 2,477 individuals (after 
quality control) from 546 families (436 complete), including 886 participants aged 2 to 17 years with diagnosed 
(n = 871) or suspected (n = 15) ASD, 218 siblings without ASD, 1,256 parents, and 117 unrelated children without an 
ASD diagnosis. The genetic data were used to confirm familial relationships and assign ancestry, which was majority 
European (n = 1,964 European individuals). We generated polygenic scores (PGS) for ASD, IQ, chronotype and height 
in the subset of Europeans, and in 3,490 unrelated ancestry-matched participants from the UK Biobank. We tested 
for group differences for each PGS, and performed prediction analyses for related phenotypes in the AAB. We called 
copy-number variants (CNVs) in all participants, and intersected these with high-confidence ASD- and intellectual dis-
ability (ID)-associated CNVs and genes from the public domain.
Results: The ASD (p = 6.1e−13), sibling (p = 4.9e−3) and unrelated (p = 3.0e−3) groups had significantly higher ASD 
PGS than UK Biobank controls, whereas this was not the case for height—a control trait. The IQ PGS was a significant 
predictor of measured IQ in undiagnosed children (r = 0.24, p = 2.1e−3) and parents (r = 0.17, p = 8.0e−7; 4.0% of 
variance), but not the ASD group. Chronotype PGS predicted sleep disturbances within the ASD group (r = 0.13, 
p = 1.9e−3; 1.3% of variance). In the CNV analysis, we identified 13 individuals with CNVs overlapping ASD/ID-associ-
ated CNVs, and 12 with CNVs overlapping ASD/ID/developmental delay-associated genes identified on the basis of de 
novo variants.
Limitations: This dataset is modest in size, and the publicly-available genome-wide-association-study (GWAS) sum-
mary statistics used to calculate PGS for ASD and other traits are relatively underpowered.
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Background
Autism spectrum disorder (ASD) is a neurodevelop-
mental condition with significant clinical heterogeneity. 
Heritability estimates are high (~ 80%), and the genetic 
architecture is complex, involving de novo, rare and com-
mon genetic variants [1]. One approach to disentangle 
this heterogeneity and understand how genetics con-
tribute to autism-associated clinical features is through 
cohort datasets that combine deep phenotypic informa-
tion with biological datasets.
In autism, the majority of the genetic variation tracked 
by heritability is accounted for by common genetic vari-
ation [2, 3], as quantified by the single nucleotide poly-
morphism (SNP)-based heritability which is estimated to 
be ~ 40–50% [2]. As with other common neuropsychiat-
ric conditions, common variants contributing to autism 
have small effect sizes, requiring large sample sizes for 
identification. The largest published ASD genome-wide 
association study (GWAS) [4] identified five genome-
wide significant loci in an analysis of 18,381 cases and 
27,969 controls, and an additional seven loci were identi-
fied using multi-trait analysis of GWAS [5] methodology 
leveraging power from correlated traits. Larger sample 
sizes will be necessary to identify further loci, which are 
expected to be found given the substantial estimate of 
SNP-based heritability [2].
De novo and rare inherited variants contribute 
to ~ 10% of diagnoses of autism [1]. They include kar-
yotype abnormalities [6], copy number variants [7] 
(CNVs) including deletions and duplications, and del-
eterious point mutations such as loss-of-function and 
missense variants [8, 9].  De novo genetic variants pre-
dominantly  do not contribute to heritability estimates, 
which only track genetic features shared by relatives. 
CNVs are of particular interest in ASD with rare, large 
CNVs being associated with ASD, as well as commonly 
co-occurring conditions such as developmental delay 
(DD) and intellectual disability (ID). De novo CNVs 
occur at three to five times the rate of controls or unaf-
fected siblings [9, 10], tend to have modest to large 
effect sizes [11, 12], and the number of affected genes is 
associated with autism propensity [9]. Although many 
forms of rare variation require sequencing approaches 
to detect, larger CNVs may be detected from genome-
wide SNP arrays using software such as PennCNV [13] 
and iPattern [10]. This is useful as it enables analysis of 
CNVs in ASD studies which include genotyping data.
The Australian Autism Biobank (AAB) [14] is an ini-
tiative of the Australian Cooperative Research Centre 
for Living with Autism (Autism CRC, website at [15]) 
that recruited individuals aged 2 to 17  years diag-
nosed with ASD, their parents and undiagnosed sib-
lings, together with unrelated  undiagnosed children 
from Australia’s four most populous states. The value 
of the AAB, although relatively modest in size, lies in 
the depth of the dataset, which includes detailed phe-
notypic data (psychological and behavioural testing, 
medical history, parental medical history, and lifestyle 
data including diet (children only), parental occupation 
and educational attainment, and parental exposures 
to psychological and chemical hazards), biospecimens 
(including blood, urine, stool, hair and saliva) and 
derived genomic data (SNP genotyping, DNA meth-
ylation, stool metagenomics, and metabolomics). This 
combination of biological data and deep phenotyping 
offers an opportunity to dissect the clinical and genetic 
heterogeneity inherent in autism.
In particular, the depth of data in the AAB lends itself 
to prediction analyses. Polygenic scoring methodol-
ogy enables prediction of phenotypes based on com-
mon genetic markers, based on the assumption that 
complex traits are underpinned by many additive vari-
ants of small effect (which are on the liability scale for 
disease traits). Polygenic scores (PGS) leverage sum-
mary statistics from independent large-scale GWAS to 
obtain effect-sizes of trait-associated alleles. Applied to 
an individual, the effect-sizes for a given allele are mul-
tiplied by that individual’s allele dosage, and summed 
over all alleles to calculate their PGS. Thus, for a given 
complex trait, an individual’s PGS estimates propensity 
for that trait, or at least that which is captured by com-
mon genetic variation. For disease traits, the PGS are 
usually called polygenic risk scores, with higher values 
implying higher risk for the disease.
Here, we present analyses using genome-wide SNP data 
from a total of 2,477 individuals in the AAB. First, we use 
these genetic data to confirm relationships and ancestry. 
Conclusions: We report on common genetic variation and rare CNVs within the AAB. Prediction analyses using 
currently available GWAS summary statistics are largely consistent with expected relationships based on published 
studies. As the size of publicly-available GWAS summary statistics grows, the phenotypic depth of the AAB dataset will 
provide many opportunities for analyses of autism profiles and co-occurring conditions, including when integrated 
with other omics datasets generated from AAB biospecimens (blood, urine, stool, hair).
Keywords: Autism spectrum disorder, Genetics, Polygenic score, Copy number variation, Australian autism biobank
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Second, we leverage publicly-available summary statis-
tics for ASD, IQ and other traits to explore the common 
genetic basis of autism in the AAB, together with a vari-
ety of phenotypes including psychometric testing results 
and diagnostic features. Third, we call CNVs and identify 
overlap with publicly-available, curated lists of CNVs and 
genes that have been associated with ASD, ID and DD.
Methods
Overview of dataset
A full description of the AAB biobank is provided by 
Alvares et  al. [14]. Participants were recruited between 
2013 and 2018 from four major autism research centres 
or developmental clinics across Australia—in Perth, Bris-
bane, Melbourne and Sydney. AAB participants fell into 
four groups: 1) child participants (aged 2–17 years) diag-
nosed with ASD or queried for the condition (hereafter 
referred to as “ASD”), with some multiply-affected fami-
lies; 2) parents of children with ASD; 3) siblings (“SIB”) 
of diagnosed children who did not themselves meet ASD 
criteria; and 4) unrelated children (“UNR”) without an 
ASD diagnosis and with no known first-degree relatives 
with an ASD diagnosis. The UNR group was recruited 
from the community: predominantly from children 
(Generation 3) of the Generation 2 participants from 
the Raine Study in Perth [16], and through community 
advertising and in association with health service provid-
ers in the other centres. This group did not have exclu-
sion criteria other than ASD diagnosis (i.e., there were no 
exclusions for other psychiatric, medical or genetic con-
ditions, cognitive function, or medication use). Detailed 
phenotypic data (see below) and multiple biological sam-
ples (blood, stool, urine, saliva, hair) were collected from 
most (but not all) participants.
Phenotype data
The AAB includes detailed phenotypic data [14]. For 
the ASD group, clinical assessments were administered 
and questionnaires were completed by parents or car-
egivers, including the Autism Diagnostic Observation 
Schedule-2 (ADOS-2) [17] or Autism Diagnostic Obser-
vation Schedule-G (ADOS-G) [17], Developmental, 
Dimensional and Diagnostic Interview [18]), Vineland 
Adaptive Behavior Scale-II [19], and the Short Sensory 
Profile-2 (SSP-2) [20]. Parents and the SIB and UNR 
groups completed age-appropriate questionnaires for 
broader autism spectrum symptoms (Parents: Commu-
nication Checklist-Adult [21]; SIB/UNR: Social Respon-
siveness Scale [22]). Cognitive functioning and IQ in the 
ASD, SIB and UNR groups was assessed using the Mullen 
Scales of Early Learning (MSEL [23]) or Wechsler Intel-
ligence Scale for Children 4th edition (WISC-IV) [24], 
and in parents using the matrix reasoning subtest of the 
Wechsler Abbreviated Scale of Intelligence 2nd edition 
(WASI) [25]. Sleep problems in the ASD, SIB and UNR 
groups were assessed with the Children’s Sleep Habits 
Questionnaire (CSHQ) [26]. Morphometric measures 
(height, weight, head circumference) were collected on 
all participants, and the dataset also includes medical his-
tory of parents and the child (including gestational his-
tory, immune disorders and gastrointestinal conditions), 
developmental milestones and early-life exposures.
We used the following summary scores from the psy-
chometric questionnaires: the ADOS-2 Calibrated Sever-
ity Score (scored from 1 to 10 indicating the level of 
ASD-related symptoms compared to children with ASD 
of the same age and language ability, from ADOS-2 Mod-
ules 1–4), the Social Responsiveness Scale total t-score, 
the CSHQ raw score (sum of items, after reversing rel-
evant questionnaire items), and a CSHQ composite score 
based on variables that were relevant to chronotype 
(items: the Sleep Onset Delay, Sleep Duration, Night 
Waking and Daytime Sleepiness subscales, in addition 
to the “goes to bed at same time” item of the Bedtime 
Resistance subscale), the Communication Checklist-
Adult z-score, the WISC-IV composite score, the WASI 
matrix reasoning t-score, and the MSEL non-verbal 
developmental quotient.
SNP genotyping quality control (QC) and imputation
SNP genotyping was initially performed on a total 2,491 
AAB participants (with 2,477 remaining after QC steps 
described below) who provided a blood sample, using the 
Illumina Global Screening Array v1 and v2. The Genom-
eStudio v2.0.4 software was used to call genotypes and 
filter low quality samples (call rate ≥ 95%) and SNPs 
(cluster separation ≥ 0.4, AB R mean ≥ 0.2, AB T mean 
0.2 ≤ x ≤ 0.8, and GenTrain score ≥ 0.68), prior to strand 
alignment and standard quality control procedures per-
formed in PLINK1.9 [27, 28]. We excluded n = 1 sam-
ple with missingness > 0.1 and SNPs with genotyping 
rate < 0.02, Hardy Weinberg equilibrium test < 1e−6 and/
or minor allele frequency < 0.01. We removed duplicated 
samples, retaining the sample with the lower missing-
ness rate. We also cross-referenced allele frequencies to 
the Haplotype Reference Consortium reference, exclud-
ing SNPs where the difference in minor allele frequency 
between the AAB dataset and Haplotype Reference Con-
sortium was greater than 0.2.
To help identify sample mix-ups, we checked for dis-
crepancies between reported and genetic sex. In the 
process of performing these checks, we identified two 
individuals with sex chromosome aneuploidies (one with 
diagnosed Turner’s syndrome (XO), and one with Kline-
felter’s syndrome (XXY) that had not been recorded in 
the AAB medical history), and n = 4 pairs (total n = 8 
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individuals) of putative sample mix-ups, which were sub-
sequently checked and corrected based on genetic rela-
tionships, and manifest sample proximity. We identified 
a further 12 individuals whose genetic sex based on X 
chromosome F coefficients of inbreeding (F coefficient) 
was inconclusive. For these individuals, we calculated 
genome-wide inbreeding coefficients, and rescued from 
exclusion female samples with X chromosome F < 0.25 
and genome-wide inbreeding coefficient ≥ 0.05, as this 
suggests that the higher X chromosome F coefficient may 
reflect some degree of consanguineous ancestry. Overall, 
n = 2 samples were excluded on the basis of sex checks.
Imputation to the Haplotype Reference Consortium 
[29] was performed using the Sanger Imputation Ser-
vice, with pre-phasing performed using EAGLE2 soft-
ware [30] which best accommodates the presence of 
offspring-mother-father trios in the data. The imputed 
SNPs underwent further QC (excluding SNPs with 
Hardy–Weinberg equilibrium p < 1e-6, minor allele fre-
quency < 0.01, info score < 0.8), leaving a total of 2,478 
participants and 7,068,672 SNPs (6,991,521 autosomal 
markers and 77,151 on chromosome X) for association 
and prediction analyses.
From called CNVs (below) we identified one child in 
the UNR group with a CNV diagnosis of Smith-Magenis 
syndrome, which is associated with DD and can present 
with autistic features. For this reason, this participant 
was excluded from subsequent analyses, after which data 
from 2,477 participants remained in the QC-ed dataset.
Ancestry assignment and genetic relationships
We inferred genetic ancestry for each individual by pro-
jecting the AAB genotyping data onto the first two prin-
cipal components (PCs) of the 1000 Genomes reference 
dataset. Ancestry was assigned if the AAB individual 
was within 4 standard deviations of the mean for a given 
population group (European, South Asian, East Asian, 
African). All other individuals were assigned to “other” 
ancestry.
For the AAB European subset (n = 1,973), we calculated 
20 PCs using GCTAv1.92 [31, 32], based on the geno-
typed SNPs, which were subsequently included as linear 
regression covariates in the PGS analyses. As input, we 
took n = 255,861 common genotyped SNPs with minor 
allele frequency > 0.05 in the Haplotype Reference Con-
sortium dataset.
Familial relationships were inferred using pairwise 
identity-by-state estimation with the PLINK1.9—
genome command. We used linkage disequilibrium-
pruning (settings: window size 250 SNPs, step size 25 
SNPs, VIF = 1.111 or equivalent to r2 = 0.1) to iden-
tify a set of 92,546 independent variants as input data. 
Relatedness checks were performed in two ways: 1) 
pairwise estimations across the entire dataset, and 2) 
pairwise estimations between self-reported family mem-
bers. This enabled inference of parent-offspring (PI_
HAT > 0.45, Z1 > 0.8, Z2 < 0.1), full-sibling (PI_HAT > 0.35 
0.3 < Z1 < 0.8, Z2 > 0.1), monozygotic twins (PI_HAT > 0.8, 
Z2 > 0.8), and half-sibling (PI_HAT > 0.1, Z1 > 0.45, 
Z2 < 0.1) relationships, whereby PI_HAT refers to the 
estimated proportion of the genome that is inherited by 
descent (IBD) (P(IBD = 2) + 0.5*P(IBD = 1)), Z1 refers to 
P(IBD = 1) and Z2 refers to P(IBD = 2). These relation-
ships were cross-referenced against the reported rela-
tionships in the AAB, and to match family members not 
otherwise linked by the ID system (e.g., where individu-
als within one family were recruited on different dates or 
assessment centres). For downstream analyses, we con-
structed a genetic relatedness matrix (GRM) from the 
SNP genotypes using GCTAv1.92 [31, 32].
To ensure consistency between child and parent geno-
types within these family sets, we also performed a check 
for Mendelian errors within families using PLINK1.9 [27, 
28], finding that the maximum parent–offspring Men-
delian error rate was ~ 0.1%, consistent with the known 
error rate on Illumina SNP arrays, and implying no unde-
tected sample mix-ups.
Polygenic scoring
Description of input GWAS summary statistics
We used summary statistics from GWAS for height [33], 
ASD [4], IQ [34] and chronotype [35]. As an indicator of 
GWAS study power, these summary statistics had 2,380, 
5,276, and 327 independent (p < 5e−8, r2 < 0.1) genome-
wide significant associations, respectively, from analyses 
of n = 345,011, n = 46,350 (18,381 cases, 27,969 controls), 
n = 269,867 and n = 697,828 individuals.
Selection of UK Biobank (UKB) controls
Given that the UNR group had minimal exclusion crite-
ria and was small (n = 117), UK Biobank (UKB) controls 
with European genetic ancestry were selected as an addi-
tional control group. These individuals were selected by 
projecting the n = 1,964 ASD participants of European 
ancestry onto the PCs derived using 137,102 genotyped 
SNPs from n = 436,227 UKB participants of European 
ancestry (GCTAv1.92,–project-loading command). For 
each ASD participant, the n = 5 UKB participants with 
the least Euclidean distance across 3 UKB principal com-
ponents were taken as controls (Additional file 1: Fig. 1).
SBayesR PGS weighting
We generated polygenic scores (PGS) using SBayesR 
[33] – a Bayesian method that takes GWAS summary 
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statistics as input. This method shrinks SNP effect sizes 
while still maximising variance explained by “binning” 
SNPs into a mixture of normally-distributed priors, 
accounting for linkage disequilibrium. SBayesR has been 
shown to outperform other PGS methods regardless of 
the underlying genetic architecture of the trait [33, 36]. 
SBayesR requires two inputs: 1) GWAS summary statis-
tics from which HapMap3 SNPs with imputation INFO 
filter > 0.8 were extracted, retaining only those SNPs that 
passed QC in both AAB and UKB and 2) linkage dis-
equilibrium matrices built using HapMap3 SNPs from 
a subset of 50,000 unrelated Europeans from the UKB. 
Additional file  2: Table  1 shows the number of SNPs 
used in each SBayesR analysis (intersection of HapMap3 
SNPs across the GWAS discovery and AAB), and Addi-
tional file 2: Table 2 shows the SBayesR output. SBayesR 
was run with the default inputs: –pi 0.95, 0.02, 0.02, 0.01; 
gamma 0, 0.01, 0.1, 1; chain-length 10,000; burn-in 2000; 
out-freq 10, and using the –exclude-mhc flag. For height 
only, there was an additional step to filter GWAS SNPs 
with the software package DENTIST [37], to remove 
inconsistent imputed Z-scores based on the linkage 
disequilibrium reference matrix and observed GWAS 
Z-scores, which improved convergence of the SBayesR 
algorithm.
PGS calculation
To generate PGS for each trait, we multiplied the best 
guess genotypes in the target sample (i.e. AAB individu-
als and UKB controls) by the effect sizes (reweighted by 
SBayesR [33], with the addition of DENTIST [37] for 
the height analysis), using the PLINK –score function. 
We restricted analyses of the target dataset to the sub-
set of participants of inferred European ancestry. The 
PGS scores were standardised by subtracting the mean 
and dividing by the standard deviation of the UKB con-
trols. We generated PGS from four sets of GWAS sum-
mary statistics: height from the UKB [33], excluding 
the controls that we had selected, ASD [4], IQ [34] and 
chronotype [35]. Height was selected as a benchmarking 
phenotype that has large GWAS discovery sample size 
and so is well-powered for PGS. ASD is of course directly 
relevant to the AAB cohort, while IQ and chronotype 
are genetically-correlated with ASD [4]. Given our small 
sample size, we eschewed analysis of additional traits to 
avoid incurring a high multiple testing burden.
Between‑group PGS differences
We tested for a mean difference in PGS for each trait 
between ASD, SIB and UNR AAB experimental groups 
using Z-tests. To improve power to test for differences, 
we added the group of unrelated controls of European 
ancestry from the UKB (as described above).
Over‑transmission of common genetic variation for ASD
We tested for over-transmission of common genetic vari-
ation for ASD from parents to their children with and 
without autism. For n = 330 individuals diagnosed with 
ASD and n = 145 undiagnosed siblings with parental 
genotyping data, we tested for polygenic transmission 
disequilibrium using the pTDT software [38]. Briefly, 
this tests for a deviation of the child’s PGS from the mid-
parental PGS (which represents the null). We also looked 
for evidence of assortative mating for ASD only. For this, 
we tested for correlation of PGS between the parental 
pairs within the family data.
Relationships between PGS and phenotypes
We calculated correlations between PGS of multiple 
traits and various phenotypes of interest recorded within 
the AAB. We calculated the proportion of variance in 
standardised phenotype residuals explained by PGS, 
where phenotype residuals resulted from regression on 
covariates that included age, sex and 20 PCs (calculated 
using GCTA on n = 255,861 common genotyped SNPs 
with minor allele frequency > 0.05 in the Haplotype Ref-
erence Consortium dataset, and only in the European 
subset of n = 1,973 for whom we generated PGS), which 
were selected for inclusion based on backwards stepwise 
regression.
Multiple testing correction
We used the Bonferroni method to correct for multiple 
testing across all PGS analyses (50 tests, p ≤ 0.05/50 or 
p ≤ 1e-3). Phenotype-PGS associations that were tested 
for both variance and correlation were counted as one 
test, as these statistics are mathematically related. With 
this threshold, we had ~ 80% power to detect a differ-
ence of 0.17 SDs in PGS mean when comparing the 
ASD (n = 697) and UKB groups (n = 3,490). For the PGS 
prediction analyses of quantitative traits, we had ~ 80% 
power to detect R2 = 0.014 in a linear regression with 1 
predictor, alpha = 1.0e−3 (after multiple testing) and 
sample size of all 1,222 children (noting that sample size 
was restricted to the available phenotype data).
Copy number variant (CNV) calling
We followed the Psychiatric Genomics Consortium CNV 
analysis pipeline [39], with a few modifications. CNVs 
were identified in each AAB individual using consensus 
calling from PennCNV and iPattern. PennCNV [13] takes 
as input signal intensity data from SNP genotyping arrays 
(Log R Ratio and genotypes), and uses a hidden Markov 
model-based approach to achieve kilobase resolution of 
CNVs [13]. In contrast, iPattern [10] takes the intrachip-
normalised X and Y values as signal intensity measures 
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and performs joint analysis across multiple individuals to 
identify CNVs.
We used the Bioconductor GenomicRanges package 
[40] to process and perform operations on genetic coor-
dinate data. Different CNV calling software may break 
up large CNVs and compromise consensus calling; to 
account for this we merged CNV calls from PennCNV 
and iPattern separately using a greedy algorithm:
1. Individuals with > 5 CNVs on one chromosome were 
identified;
2. For that individual, CNVs were split into type (gain 
or loss), as an artificially-split CNV should have con-
cordant type across its segments;
3. Adjacent CNVs with gaps ≤ 100 kb were merged in a 
greedy algorithm;
4. Adjacent CNVs with gaps ≤ 25% of the length of the 
neighbouring CNV were merged in a greedy algo-
rithm.
We obtained consensus CNV calls for each individual 
by intersecting CNV calls from both methods and retain-
ing those with ≥ 50% overlap, ensuring that copy num-
ber (gain or loss) was matching in each method. A total 
of 10,752 consensus CNVs were identified using this 
approach.
Sample QC was performed using summary statistics 
from the PennCNV output. We removed n = 137 sam-
ples where any of the LRRSD (Log R Ratio), BAFSD (B 
Allele Frequency Standard Deviation) or GCWF (GC-
content Wave Form) statistics (based on autosomal data) 
had a value more than three standard deviations from the 
mean. We also applied a filter for samples where CNVs 
made up greater than 20% of any chromosome to exclude 
aneuploidy. This step identified n = 2 individuals – one 
participant from the ASD group with known Down syn-
drome (trisomy 21), and one participant with diagnosed 
Smith-Magenis syndrome whom had been included in 
the UNR group. CNVs were excluded if:
1. the PennCNV confidence score was < 10;
2. there was any overlap with centromeres or the major 
histocompatibility complex region (hg19 coordinates 
chr6:28,477,797–33,448,354), the latter due to the 
complexity of this region;
3. there was > 50% overlap with a segmental duplication;
4. the CNV was common. This was determined by 
firstly identifying genomic regions that were over-
lapped by 25 or more CNVs (a threshold of 25 was 
chosen as this corresponds to ~ 1% of the AAB popu-
lation). CNVs with ≥ 50% overlap with these regions 
were considered “common” and therefore excluded;
5. the CNV was < 10 SNPs in length and/or < 20  kb in 
length;
6. the CNV was common or benign: defined as ≥ 70% 
overlap with CNVs classified as benign by Zarrei 
et  al. [41] using their “inclusive” criteria; considered 
as common in the DECIPHER study[42]; or maxi-
mum frequency across populations ≥ 1% in the gno-
mAD v2 dataset [43, 44]; and
7. the CNV overlapped exclusively with non-coding 
regions, as determined using RefSeq hg19 gene anno-
tation coordinates[45]; and
8. the CNV was non-genic.
After QC, we excluded one additional individual for 
whom 21 CNVs had been called (the next-highest num-
ber of CNVs for an individual was four), leaving 885 
CNVs from 723 individuals remaining for subsequent 
analysis.
CNV annotation
We annotated CNVs using hg19 cytoband and gene 
coordinates imported from biomaRt [46]. We defined 
cytoband overlap when ≥ 50% of the called CNV length 
lay within the cytoband. Gene overlap was defined as 
any overlap with coding exons. We checked for overlap 
between CNVs in the AAB dataset and a total of 51 path-
ogenic CNV regions involved in neurodevelopmental 
conditions selected from clinical databases (ClinGen [47] 
and DECIPHER [48, 49]) for being associated with ASD 
and ID. To define overlap, we divided pathogenic ASD/
ID CNVs into those with and without a critical gene. 
CNVs with a critical gene required overlap with any exon, 
whereas CNVs without a critical gene required ≥ 80% of 
the pathogenic CNV region. We also looked for overlap 
of the AAB CNVs with the 102 genes identified by the 
largest whole exome sequencing study of ASD to date 
[12], and 93 genes associated with developmental dis-
orders from the Deciphering Development Disorders 
(DDD) study [50] – a total of 158 unique genes.
Results
Characteristics of the Australian Autism Biobank (AAB)
A summary of familial relationships and genetic ances-
try in the AAB is provided in Fig. 1. AAB participants 
passing genotyping QC (n = 2,477 individuals, n = 546 
family groupings, n = 436 families with both parents 
and at least one affected child) were predominantly 
of European ancestry (n = 1,964 individuals, n = 323 
families, n = 154 families with more than one child in 
the AAB), with representation from other populations 
including South Asian (n = 248 individuals, n = 26 
families), East Asian (n = 45 individuals, n = 7 families) 
and African (n = 10 individuals, n = 1 family). All other 
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Fig. 1 Characteristics of the AAB dataset. a Diagram showing cohort relationships. b Counts of familial relationships, split by ancestry. Ancestry is 
assigned to a family if the entire family is of the same genetic ancestry. N: total number of individuals in each ancestry group. Families: the number 
of families with both parents and at least one child. Subsequent rows (“n = ”) demonstrate the breakdown by family size (e.g., n = 3 denotes trios, 
n = 4 denotes quartets, and so on). The numbers in brackets refer to the number of families with one child on the autistic spectrum versus the 
number of families with multiple children on the autistic spectrum. c) Genetic ancestry of AAB individuals projected onto the first two principal 
components of the 1000 Genomes reference dataset. Pink denotes the AAB group. Acronyms for ancestry groups: AFR, African; AMR, American 
(Central and South) ; EAS, East Asian; EUR, European; SAS, South Asian. d) Overview of analyses performed, divided into common SNP analyses 
(upper) and rare copy-number variation analyses (lower). The number of tests used to calculate Bonferroni correction are also displayed
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individuals of admixed ancestry were classified into 
an “Other” group (n = 211 individuals, n = 79 families, 
n = 21 families with more than one child in the AAB) 
(Fig.  1b). For families with multiple participating chil-
dren (i.e., total family n > 3), Fig.  1b also summarises 
the number of families with one child on the spectrum 




Using the PGS from each AAB participant of European 
ancestry, we first tested whether there were group dif-
ferences in genetic propensity for various traits. As 
a negative control, we found no differences in mean 
height PGS (Additional file  1: Fig.  2, Additional file  2: 
Table  3). We next tested autism-associated traits. The 
mean of the ASD PGS was higher in the ASD group 
(p = 6.1e−13) than the UKB group after multiple-test-
ing correction (Fig.  2) (Additional file  2: Table  3). The 
SIB (p = 4.9e−3) and UNR (p = 3.0e−3) groups also 
had higher mean ASD PGS than the UKB at a nomi-
nal threshold (Fig. 2) (Additional file 2: Table 3). There 
was no evidence for a significant difference in mean 
ASD PGS between the ASD and SIB groups in the AAB, 
or between ASD and UNR controls (Fig.  2a). IQ is of 
interest in relation to ASD as ID commonly co-occurs, 
and yet there is positive genetic correlation based on 
common SNPs. For IQ PGS, we observed no difference 
between groups in the AAB, nor with the UKB controls, 
after multiple testing correction (Fig.  2b). We investi-
gated chronotype as sleep disturbances also commonly 
co-occur with autism [51]. We did not find differences 
in chronotype PGS between the ASD, SIB and UNR 
groups in the AAB (Additional file 1: Fig. 2, Additional 
file 2: Table 3). For chronotype, we did not test for dif-
ferences between AAB groups and the UKB controls, as 
the input GWAS also included UKB participants.
Over‑transmission of genetic variation for ASD
The pTDT analysis provided no evidence for difference in 
ASD or IQ PGS between the ASD and SIB groups (Addi-
tional file 2: Table 4). We did not find evidence of assorta-
tive mating between parental pairs on the basis of ASD 
PGS (n = 324 European pairs, r = 0.06, p = 0.28), nor in 
the analysis of height PGS (r = 0.09, p = 0.11), likely due 
to the small size of this subset.
Prediction of autism and related phenotypes
The deep phenotypic data included in the AAB allowed 
us to leverage publicly-available GWAS summary statis-
tics to perform prediction analyses into our dataset.
Height:  Height is considered a model genetic trait 
because it is highly heritable and summary statistics 
from very large GWAS are available. We used height 
as a control trait, and to validate our analysis pipeline, 
because it is not expected to exhibit differences between 
the participant groups (although a higher proportion 
of participants in the ASD than SIB groups would be 
expected to carry major de novo CNVs associated with 
reduced stature [52]). We considered adults and chil-
dren separately, as adults have stable height, and should 
be predicted more accurately. In the subset of AAB 
adults, height was strongly correlated with height PGS 
(r = 0.37, p = 1.0e−30; correlation on residuals after 
adjusting for age and sex: r = 0.52, p = 2.7e−66), and the 
PGS accounted for 27% of the variance after adjusting 
for covariates (Additional file 2: Tables 5, 6). In compari-
son, height PGS in AAB children captured only 13% of 
the variance (correlation: r = 0.14, p = 9.2e−11), presum-
ably because of age effects (Additional file  2: Table  6). 
As expected, there was no evidence for between-group 
differences in height PGS or for over-transmission of 
common genetic variation for height in the ASD group 
compared to the SIB group (Additional file 2: Tables 3, 4). 
Thus, the height analysis performed as expected, justify-
ing the use of the UKB control group and is consistent 
with no residual genetic stratification between the AAB 
groups and the UKB controls.
ASD: We determined whether the ASD PGS based on 
Grove et al. [4] predicted diagnosis of ASD in the AAB, 
in addition to other ASD-related phenotypes, including 
ADOS-2 calibrated severity score within the ASD group, 
Social Responsiveness Scale t-score in the SIB and UNR 
groups, and the Communication Checklist-Adult in par-
ents. These tests were chosen as there were no autism 
spectrum questionnaires that were available across 
all participant groups. We also tested for association 
between ASD PGS and indicators for age of onset (age 
of first parental concern and age of diagnosis) and other 
ASD-associated phenotypes, including Short Sensory 
Profile-2 raw score (only available in the ASD group), 
WISC-IV composite score (or MSEL non-verbal devel-
opmental quotient) in children and WASI matrix reason-
ing score in parents. For cognitive ability phenotypes, we 
also stratified children into ASD and SIB/UNR groups, 
as we hypothesised that—given positive genetic correla-
tion with autism [4]—the ASD PGS may have different 
relationships with IQ or developmental quotient depend-
ing on diagnostic status. No associations (passing Bon-
ferroni correction) were found between ASD PGS and 
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ASD diagnostic status, likely because the ASD GWAS is 
underpowered. However, there were nominal associa-
tions between ASD PGS and quantitative traits such as 
MSEL non-verbal developmental quotient (r = -0.11, 
p = 7.4e−3 in the ASD group alone) and marginal asso-
ciation with parental WASI matrix reasoning score 
(r = 0.07, p = 5.5e−2) (Additional File 2: Tables 5, 6).
IQ:  IQ is a trait of interest as others have reported 
positive genetic correlation with autism [4], which is 
paradoxical as ID commonly co-occurs with autism. 
Hypothesising that diagnostic status may affect the rela-
tionship, we considered ASD and SIB/UNR groups sepa-
rately. IQ PGS showed a significant positive correlation 
with parental IQ, as measured by the WASI matrix rea-
soning domain (r = 0.17, p = 8.0e−7) (Fig. 2c, Additional 
File 2: Table  5), and captured 4% of the variance of the 
residuals of the baseline model (model p = 2.85e−9) 
(Additional File 2: Table  6). There was a nominally-
significant correlation between IQ PGS and WISC-IV 
composite score (Fig. 2d-e, Additional File 2: Table 5) in 
the SIB/UNR group (r = 0.24, p = 2.1e−3) (Fig.  2e), and 
within this group, the IQ PGS explained 6.7% of variance 
(p = 6.0e−4, an additional 213% compared to 3% from 
the baseline model) and made a significant contribution 
to the model (beta = 3.21, p = 6.0e−4) (Additional File 
2: Table 6). In contrast, there was no evidence for a sig-
nificant correlation in the ASD group (r = 0.07, p = 0.24) 
(Fig.  2d, Additional File 1: Fig.  5, Additional File 2: 
Table 5), including when the ASD group was stratified by 
ID (Additional File 1: Fig. 5b). In the corresponding vari-
ance analysis within the ASD group, the PGS captured 
0.4% of variance in addition to the baseline model, which 
was not significant (p = 0.12) (Additional File 2: Table 6). 
There were no significant relationships between IQ PGS 
and MSEL non-verbal developmental quotient, age of 
diagnosis, age of parental concern, and Short Sensory 
Profile-2 raw score (Additional File 2: Table 5).
To screen for ascertainment bias in relation to over-
lap between ASD and IQ, we looked for relationships 
between mid-parental matrix reasoning IQ score and 
both age of diagnosis and ID in their children. There 
was no correlation between age of diagnosis and mid-
parental matrix reasoning IQ, but we note that the 
distribution had a slight right-shift in distribution in mid-
parental matrix reasoning IQ in trios where the child 
did not have ID (defined as WISC-IV IQ comparison 
score ≥ 70)      (Additional File 1: Fig. 6).
Chronotype: Sleep issues are common among people 
on the spectrum [53, 54], so we investigated whether 
common genetic variants contribute to propensity for 
sleep conditions. There was no evidence for a signifi-
cant correlation between chronotype PGS and CSHQ 
raw score among all children  (r = 0.06, p = 7.7e−2), but 
we observed a nominally-significant positive correlation 
(r = 0.13, p = 1.9e−3) in the ASD group  (Fig.  2f, Addi-
tional File 1: Fig. 7, Additional File 2: Table 5). Within the 
ASD group, the chronotype PGS explained 1% of the var-
iance (p = 3.4e−3) in CSHQ score, a 34% increase com-
pared to the baseline model, which had adjusted  R2 = 4% 
(Additional File 2: Table 6, Additional File 1: Fig. 7).
Copy number variants (CNVs)
We obtained consensus calls for 885 CNVs from 723 
individuals in the AAB cohort after QC (summarised in 
Table 1). As a first step, we determined whether our pipe-
line validated previously-identified pathogenic CNVs. 
Seven out of eight clinical genetic diagnoses (Additional 
file  2: Table  8a) were identified by both PennCNV and 
iPattern, with the exception of an individual with Phelan-
McDermid syndrome (caused by a 6,635  bp 22q13 
deletion of chr22: 51,159,408–51,166,043), which was 
detected by PennCNV, but not by iPattern. Of the seven 
remaining, one child with Smith-Magenis syndrome 
whom had been assigned to the UNR group was removed 
Table 1 Summary of CNV statistics between groups
n_all, number of individuals within the entire group; n_ind, number of individuals with a rare exonic CNV in the group; n_CNV, number of rare exonic CNVs in that 
group; % with CNV, % of individuals with a rare exonic CNV. no. median, median number of rare exonic CNVs; no. mean, mean number of rare exonic CNVs; ASD/ID 
CNV del, number of rare exonic deletion CNVs overlapping with the ClinGen + DECIPHER deletion CNV set; ASD/ID CNV dup, number of rare exonic duplication CNVs 
overlapping with the ClinGen + DECIPHER duplication CNV set; ASD/ID/DD genes del, number of rare exonic deletion CNVs overlapping with the Satterstrom et al. 
(2020) + DDD (2017) gene set; ASD/ID/DD genes dup, number of rare exonic duplication CNVs overlapping with the Satterstrom et al. (2020) + DDD (2017) gene set 
(100% overlap required)








ASD 885 263 330 29.72 0 0.37 11 4 5 3
FTR 504 134 167 26.59 0 0.33 0 0 1 0
MTR 752 232 280 30.85 0 0.37 3 0 3 0
SIB 218 57 68 26.15 0 0.31 0 0 0 0
UNR 116 37 40 31.90 0 0.34 0 0 0 0
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from subsequent analyses; two had CNVs that did not 
survive the QC filters (one overlapped with a contig 
region with poor-quality mapping, whereas another was 
purely intronic); and two events were not in the Clin-
Gen + DECIPHER CNV set (Additional file 2: Table 8a). 
We also note that the genotyping QC process identified 
one child in the ASD group with Turner syndrome (XO) 
and one child in the UNR group with Klinefelter syn-
drome (XXY).
CNV annotation
We identified 13 individuals with CNVs that overlapped 
high-confidence ASD/ID-associated CNVs from the 
ClinGen [47] and DECIPHER [48, 49] databases (Table 1, 
Additional file  2: Table  7a, b). Four of these CNVs had 
been reported in the AAB phenotype dataset (a total 
of eight had been reported, Additional file  2: Table  8a), 
although it is important to note that there was no formal 
field for genetic diagnosis, and those that were recorded 
were offered by parents in response to the child’s medi-
cal history. Ten of these were from the ASD group, and 
three from their mothers. The phenotypic data of the 
participants with overlapping ASD/ID-associated CNVs 
was closely inspected, finding that many of these par-
ticipants had reported one or more clinical features that 
were consistent with the genetic diagnoses, including 
DD, ID (measured using WISC-IV or diagnosed previ-
ously), history of seizures, macrocephaly and/or sleep 
disturbances (Additional file 2: Table 8b). We also iden-
tified large CNVs that were > 1  Mb in length, among 
participants whom did not have an ASD/ID-associated 
CNV. There were 37 individuals whom met these criteria 
(19 ASD, 1 SIB, 3 UNR, 11 mothers, 3 fathers), includ-
ing some that were inherited, or demonstrated familial 
patterns: a 1.3 Mb 16p23.1 deletion occurring in a father-
child (ASD) pair, a 1.9  Mb 2q37.3 deletion occurring in 
a mother–child (ASD) pair, a 2.4 Mb 4q35.2 duplication 
occurring in a mother and two of her children (both in 
the UNR group), and an identical twin pair (both in 
the ASD group) sharing a 2.3  Mb 1p34.2 deletion. The 
genetic coordinates, corresponding cytobands and phe-
notypic information for these individuals are provided in 
Additional file 2: Table 8c.
A further 12 individuals (Tables 2, 3, Additional file 2: 
Table  8d) were found to carry CNVs overlapping with 
coding sequences of genes in either the list of ASD-
associated genes identified in the most recent ASD 
whole-exome sequencing study [12] or the list of genes 
associated with DD reported by the DDD study [50] 
(Additional file  2: Table  7b). Eight of these CNVs were 
identified in the ASD group and four were present in 
parents (three of which appeared to be transmitted to 
children, and are displayed in Table 3; CNV information 
for the additional parent is provided in Additional file 2: 
Table 8d).
A density plot of CNV regions (separated into deletions 
and duplications from the ASD/ID-associated CNV data-
set) across all individuals, in relation to chromosome, 
cytoband, ASD/ID-associated CNVs and ASD/ID/DD 
-associated genes is provided in Fig. 3.
Discussion
We report on polygenic variation and rare ASD/ID-asso-
ciated CNVs within the AAB dataset [14]. We first char-
acterised the genetic ancestry and family relationships of 
participants (Fig. 1). We next performed analyses of ASD 
PGS, finding that the ASD group had significantly higher 
PGS than UKB controls after multiple-testing correction. 
There were no significant relationships between the ASD 
PGS and many phenotypes relating to autism and related 
traits, likely because the ASD GWAS is still relatively 
underpowered; we anticipate that future releases of larger 
GWAS meta-analyses from the Psychiatric Genomics 
Consortium should improve prediction. In contrast to 
the ASD phenotype, we identified PGS-phenotype asso-
ciations for IQ in the SIB/UNR groups and among par-
ents that survived multiple testing correction, as well as 
nominal associations between chronotype and CSHQ 
score in the ASD group in both the correlation and vari-
ance analyses. This result is expected, as the contribut-
ing GWAS summary statistics are better-powered. From 
a rare variation standpoint, we also called CNVs, and 
found overlap with high-confidence ASD/ID-associated 
CNVs and genes in a subset of AAB participants. A major 
strength of this dataset is the breadth of its phenotyping 
and biological sample collection, which facilitates inte-
gration with other autism-focused datasets such as the 
Simons Simplex Collection (SSC) and Simons Founda-
tion Powering Autism Research for Knowledge (SPARK); 
a summary of overlapping phenotypes is provided in 
Additional file 2: Table 9.
We found that the ASD group had significantly higher 
ASD PGS scores compared to UKB-selected controls 
that passed multiple-testing correction (p = 6.6e−13); 
however, there were no significant differences between 
the AAB groups. This may be explained by the small size 
of these groups in relation to the UKB control group, or 
alternatively, it may reflect increased ASD risk within all 
AAB groups compared to the population, which is pos-
sible given the recruitment setting and lack of exclusion 
criteria. We also found nominal evidence of over-trans-
mission of ASD risk in the pTDT analysis (p = 5.8e−2), 
consistent with observations of over-transmission of 
common genetic risk in families with a child diagnosed 
with ASD [38]. These weak associations likely reflect 
small sample size within the AAB, and insufficient power 
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in the discovery ASD GWAS [4]. To confirm that PGS 
differences between the AAB groups and UKB controls 
were not a reflection of residual population stratification, 
we compared PGS for height between AAB groups and 
UKB controls and found no differences.
There is a paradoxical relationship between genetic 
risk for autism and IQ, insomuch as a positive genetic 
Table 2 ASD/ID-associated CNVs detected in the AAB dataset
ASD/ID-associated CNVs were taken from ClinGen [47] and DECIPHER [48] datasets, filtering for ASD/ID-associated loci. For reference CNVs with a critical gene, AAB 
CNVs were annotated where there was any overlap with the critical gene, with the critical gene coordinates provided in the "Other information" column. For reference 
CNVs without a critical gene, the AAB CNV was called as overlapping with an ASD/ID-associated CNV based on ≥ 80% overlap with the reference coordinates, with 
percentage overlap provided in the "Other information" column. Genome coordinates are hg19. Biobank Sample IDs have been anonymized
*Refers to parent–child pairs between which ASD/ID-associated CNVs appeared to be inherited in this dataset
^Note that the CNV for ID 1101366 only overlaps the YWHAE critical gene
Diagnosed children
Sample ID Group Sex Type CNV coordinates ASD/ID-associated CNV Reference coordinates Other information
CNVs with a critical gene
1101366 ASD M Dup chr17:1,196,088–
1,326,656
17p13.3 (Miller-Dieker 
syndrome) region (includes 
YWHAE and PAFAH1B1)^





1101637 ASD M Dup chr17:29,111,368–
30,343,735
17q11.2 recurrent region 
(includes NF1)
chr17:29,097,069–30,264,027 Critical gene coordi-
nates: chr17:29,422,328–
29,701,173
CNVs without a critical gene
4406214 ASD F Dup chr15:22,321,690–
32,515,100
15q11q13 recurrent (PWS/AS) 
region (BP1-BP3, Class 1)
chr15:22,832,519–28,379,874 100.00% overlap
3305166 ASD M Del chr15:29,079,105–
32,515,100
15q13.3 recurrent region 
(D-CHRNA7 to BP5) 
(includes CHRNA7 and 
OTUD7A)
chr15:32,019,621–32,445,405 100.00% overlap
1101486 ASD M Del chr15:31,007,901–
32,515,100
15q13.3 recurrent region 
(D-CHRNA7 to BP5) 
(includes CHRNA7 and 
OTUD7A)
chr15:32,019,621–32,445,405 100.00% overlap
1101365 ASD M Del chr15:31,115,226–
32,515,100
15q13.3 recurrent region 
(D-CHRNA7 to BP5) 
(includes CHRNA7 and 
OTUD7A)
chr15:32,019,621–32,445,405 100.00% overlap






3305177 ASD M Del chr16:28,832,565–
29,044,745
16p11.2 recurrent region 
(distal, BP2-BP3) (includes 
SH2B1)
chr16:28,822,635–29,046,499 94.78% overlap
1101491 ASD F Del chr22:18,877,787–
21,461,607
22q11.2 recurrent (DGS/VCFS) 
region (proximal, A-D) 
(includes TBX1)
chr22:15,912,231–21,465,672 99.84% overlap
4406202 ASD F Del chrX:6,488,784–
8,135,053










2215012 MTR F Del chr22:19,036,154–
20,244,259
22q11.2 recurrent (DGS/
VCFS) region (proximal, A-B) 
(includes TBX1)
chr22:18,912,231–20,287,208 87.86
1116571 MTR F Del chrX:6,456,940–
8,135,053
Xp22.31 recurrent region 
(includes STS)
chrX:6,455,812–8,133,195 99.93
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Fig. 2 PGS results: Mean PGS ± 95% CI for the ASD, SIB and UNR groups for a ASD, and b IQ (Additional file 2: Table 3). Scatterplots illustrating 
correlation between the following pairs of traits, with coefficient and p-value in the bottom right corner of each panel for the single combined 
analysis: c IQ PGS and measured IQ (WASI) in parents with fathers in red and mothers in green (overall r = 0.17, 8.0e−7); d IQ PGS and measured IQ 
(WISC fsiq composite) in the AAB ASD group with IQ < 70 (red), ASD group with IQ ≥ 70 (green), SIB group (blue) and UNR group (purple), (overall 
r = 0.1, p = 4.0e−2); e IQ PGS and measured IQ (WISC fsiq composite) in the SIB (red) and UNR (green) groups (overall r = 0.24, p = 2.1e−3); (f ) 
chronotype PGS and Children’s Sleep Habits Questionnaire in the ASD (red), SIB (green) and UNR (blue) groups (overall r = 0.06, p = 7.7e−2). The 
correlation coefficient for the ASD subset in red is r = 0.13, p = 1.9e−3)
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correlation exists between autism and IQ based on com-
mon SNPs [4], but ASD frequently co-occurs with ID. 
Hence, we investigated the genetic relationship between 
IQ and autism in the AAB. We found no evidence for a 
relationship between IQ PGS and measured IQ in the 
ASD subset with ID (defined as IQ < 70) (Fig.  2d, Addi-
tional file 1: Fig. 5b), consistent with the prevailing view 
that this co-occurring condition reflects overlapping rare 
genetic variation, rather than the common variation cap-
tured by PGS [56]. This was also supported by the finding 
that there were no statistically-significant differences in 
ASD and IQ PGS between the ASD and SIB groups.
Sleep disturbances are commonly comorbid with 
autism [51], and the most recent ASD GWAS identified a 
positive genetic correlation with chronotype [4]. Consist-
ent with this, we found a nominally-significant positive 
correlation (r = 0.13, p = 1.9e−3) between chronotype 
PGS and CSHQ raw score in the ASD group, as well as a 
nominally-significant contribution to the baseline model 
(% change = 34.4%, increase in R2 from the PGS = 0.01, 
p = 3.4e−3) (Additional file 1: Fig. 7). These associations 
were not evident in the SIB and UNR groups (Fig.  2, 
Additional file  1: Fig.  7). In the chronotype GWAS, the 
phenotype was scored from −  2 to 2, as a spectrum 
from “definitely evening” to “definitely morning” people, 
respectively. Hence, the results here suggest that sleep 
disorders among the ASD group are associated with 
common genetic variation for greater “morningness”. We 
note that the CSHQ raw score captures a wide variety of 
sleep disturbances, in addition to differences in chrono-
type. However, when we generated a composite core of 
questionnaire items that were more directly relevant to 
chronotype, there was no significant correlation with 
chronotype PGS (Additional file  2: Table  5). This may 
suggest that variants associated with chronotype magnify 
broad sleep disturbances in the ASD group.
We also looked for evidence of assortative mating by 
correlating ASD PGS scores in spouse-pairs (Additional 
file 1: Fig. 4), but did not find any significant correlation 
(r = 0.06, p = 0.28, n pairs = 324). We also performed this 
analysis for height, again finding no significant evidence 
for assortative mating (r = 0.09, p = 0.11, n pairs = 322). 
In both analyses, the point estimates are consistent with 
reported assortative mating correlations [57, 58], and our 
sample size contributes to the non-significance of the 
estimates.
For both height and IQ, PGS was a superior predictor 
in parents compared to children (Additional file 1: Fig. 3, 
Additional file  2: Tables  5, 6). This may be related to 
greater “stability” in measured phenotypes in adults (e.g., 
Table 3 List of genes from the Satterstrom et al. (2020) whole-exome sequencing study [12] and DDD study (2017) [50], 
overlapping with CNVs in the AAB dataset
Genes associated with ASD, ID and DD were taken from the Satterstrom et al. whole-exome sequencing study [12], and the DDD gene set [50]. If the AAB CNV was 
a deletion, gene overlap was called if there was any exonic overlap; if the CNV was a duplication, gene overlap was called if there was full overlap. A full list of CNVs 
overlapping ASD/ID/DD-associated genes – including those from parents that were not transmitted to children in the dataset – is provided in Supplementary Table 8d
*, + ,^ denote CNVs shared by individuals within the same family (either inherited from parents, or shared between siblings), suggesting inheritance. CNV, copy 
number variant






  1101306* ASD F chr2:148,730,454–148,883,419 MBD5 methyl-CpG binding domain protein 5 21 2q23.1
  1101211+ ASD M chr10:27,978,030–28,041,669 MKX mohawk homeobox 78 10p12.1
  3305052 ASD M chr19:10,609,319–12,464,434 ELAVL3 ELAV like neuron-specific RNA binding protein 3 100 19p13.2
  4406296^ ASD M chr20:61,824,507–62,321,517 KCNQ2 potassium voltage-gated channel, KQT-like sub-
family, member 2
100 20q13.33
  4406297^ ASD M chr20:61,802,599–62,268,955 KCsNQ2 potassium voltage-gated channel, KQT-like sub-
family, member 2
100 20q13.33
  1101417 ASD M chr2:32,277,654–32,818,823 SPAST spastin 100 2p22.3
  1101240 ASD M chr4:6,104,865–7,415,038 KIAA0232 KIAA0232 100 4p16.1
  4406214 ASD F chr15:22,321,690–32,515,100 GABRB3 gamma-aminobutyric acid (GABA) A receptor, 
beta 3
100 15q12
 Parents transmitting CNVs
  1116306* Mother F chr2:148,730,454–148,883,419 MBD5 methyl-CpG binding domain protein 5 21 2q23.1
  1116211+ Mother F chr10:27,978,030–28,041,669 MKX mohawk homeobox 78 10p12.1
  4411296^ Mother F chr20:61,802,599–62,321,517 KCNQ2 potassium voltage-gated channel, KQT-like sub-
family, member 2
100 20q13.33
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negligible effect of age in height among adults, compared 
to variability in child growth rate), and also because these 
GWAS were conducted in adults.
We note that iPattern failed to identify one individual 
whom had been diagnosed with Phelan-McDermid syn-
drome (caused by a 22q13 deletion), whereas this was 
identified by PennCNV (called CNV length = 6.6  kb, 
which is small for 22q13 deletions, which are usually 
142  kb in size). This reflects the increased sensitivity of 
PennCNV, as CNVs are called on an individual basis, 
whereas iPattern calls CNVs within batches.
Limitations
Our study has a number of limitations. Firstly, autism 
is highly heterogeneous, both genetically and clini-
cally, necessitating large sample sizes for discovery. 
Hence, we downplay the risk of the identified CNVs 
that are not already known to overlap high-confidence 
Fig. 3 Karyograms showing location and density of deletion and duplication CNVs identified in the AAB cohort. Red density track represents CNVs 
detected in the ASD subset. Blue density track represents CNVs detected in the non-ASD subset (undiagnosed siblings, unrelated undiagnosed 
children, and parents), noting that there are instances in which parents have CNVs overlapping ASD/ID-associated regions. Yellow regions depict 
ASD/ID-associated CNVs from ClinGen [47] and DECIPHER [48, 49] (Additional file 2: Table 7a). Green regions denote ASD/ID/DD-associated genes 
reported by Satterstrom et al. [12] and DDD [50] (Additional file 2: Table 7b). Karyogram generated using the karyoploteR package [55]
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ASD-associated CNVs. Insufficient power is also an issue 
for the ASD GWAS summary statistics that were used to 
calculate PGS. The availability of better-powered GWAS 
in the near future should improve the power of the pre-
diction analyses performed here. We hope that this data-
set will contribute to future meta-analyses. Furthermore, 
our sample is relatively small, particularly in relation to 
the SIB and UNR groups, and the results require replica-
tion in independent datasets to be generalisable.
We note that the UNR group had higher mean ASD 
PGS and lower mean IQ PGS than might be expected in 
a community sample (Fig. 2a,b). However, this group was 
comparatively small (n = 117), and the standard errors 
are large, so it is difficult to draw further inference from 
these results. The majority of UNR participants were 
recruited from community settings, but some were con-
tacted through association with health care providers and 
there were minimal exclusion criteria (ie., no diagnosis of 
ASD), which could contribute to the observed results.
In our PGS analyses, we remained cognisant of mul-
tiple-testing issues. We selected the statistical tests we 
performed in a hypothesis-driven manner and applied 
a Bonferroni correction across all p values calculated in 
this analysis. However, there are other interesting PGS-
phenotype relationships that may be interrogated in the 
AAB that we opted not to test, given the power of the 
current datasets available to us.
We used genetic PCs as covariates in our analysis, and 
also to select UKB controls. Like many genetic analyses 
of this nature, we acknowledge that it is difficult to bal-
ance the competing issues of residual population stratifi-
cation with the potential for over-correction. To address 
the former, we matched UKB controls within 2 standard 
deviations across 3 UKB European PCs (the maximum 
possible to achieve matching of n = 5 UKB individuals 
per AAB participant), and included 20 PCs from the AAB 
European cohort in the regression models. To account 
for the latter, we used a backwards stepwise model to 
only select the most salient genetic PCs as covariates. 
Our PGS analyses for height provided support that the 
AAB and UKB samples were genetically well-matched.
We note that our ability to call CNVs using SNP gen-
otyping data is limited in resolution and sensitivity. 
Whole-genome sequencing is the gold-standard; how-
ever, this data has not yet been generated in the AAB 
cohort.
Conclusions
Here, we characterise common genetic variation and 
rare ASD/ID-associated CNVs in the AAB cohort using 
SNP genotyping and demonstrate the utility of leverag-
ing publicly-available data to predict traits within the 
AAB’s accompanying deep phenotypic dataset. We dem-
onstrate that PGS for IQ, chronotype and height predict 
these phenotypes within the AAB dataset, and we iden-
tify individuals carrying ASD and ID-associated CNVs. 
Although this sample is not powered for discovery, these 
results will be important to integrate into future analyses 
of other omics datasets available within the AAB.
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Additional file 1. Figure 1 First two principal components of the UK 
Biobank European subset (orange). Black dots denote the projection 
of the AAB ASD participants of European ancestry (n=698) onto the 
UK Biobank principal components. Blue dots denote the UK Biobank 
individuals selected as controls (n=5 per ASD participant). Figure 2 
Comparison of mean PGS +/- 95% confidence intervals for a) height 
and b) chronotype. Note that for chronotype, the input GWAS summary 
statistics were not fully independent due to overlap with UK Biobank 
participants.  Figure 3 Correlation between height PGS and measured 
height in a) adults and b) children. Correlation coefficient and p-values are 
provided in the bottom right corner of each plot.  Figure 4 Correlation 
between maternal and paternal ASD PGS.  Figure 5 Correlation between 
IQ PGS and measured IQ (WISC-IV in children; WASI matrix reasoning in 
adults) for a) all children, b) ASD only and stratified by IQ<70, c) SIB/UNR 
groups, d) parents. Correlation coefficient and p-values are provided in 
the bottom right corner of each plot.  Figure 6 Relationships between 
mean parent matrix reasoning IQ and child traits. a) Correlation between 
child’s age of ASD diagnosis and mean parent matrix reasoning IQ score 
(r=0.01, p=0.87). b) Density plot (n families = 249) for mean parent matrix 
reasoning IQ score, stratified by the presence of ID in their child.  Figure 7 
Correlation between chronotype PGS and Children’s Sleep Habits Ques-
tionnaire (CSHQ) among a) all children, and b) the ASD group. Correlation 
coefficient and p-values are provided in the bottom right corner of each 
plot.
Additional file 2.  Table 1 Numbers of SNPs from each GWAS, and 
number remaining after QC (retaining SNPs in all of HapMap3 reference, 
UKB genotyping and AAB genotyping).  Table 2 SBayesR parRes output. 
Table 3   Statistics for tests of comparison of PGS between groups (ASD, 
SIB, UNR, UKB). Table 4 pTDT analysis results. Table 5 Summary of statistics 
for PGS correlations.  Table 6 Variance explained by the PGS.  Table 7a List 
of ASD/ID-related CNVs aggregated from ClinGen and DECIPHER. b List of 
ASD/ID/DD-related genes aggregated from Satterstrom et al. (2020) and 
DDD Study (2017) and overlapping with ENSEMBL hg19 gene set. Note 
that some genes are repeated as there are multiple transcripts that were 
considered for overlap. Table 8a: Identified CNVs in the AAB correspond-
ing with CNVs reported by parents in the AAB medical history survey. 
Please note that this information is limited to that which was reported 
by parents, and is intended to be used to help assess replication in our 
pipeline.  b Phenotypic correlates of called AAB CNVs overlapping ClinGen 
and DECIPHER CNVs. clingen_ddd.* provides start, end and widths of 
reference CNVs; critgene.* provides start and end of critical gene/s within 
reference CNVs; overlap_pcent refers to the % overlap of the called CNV, 
as a proportion of the ClinGen and/or DECIPHER-defined CNV.  c Large 
CNVs (>1 Mb) identified within the AAB.  d CNVs overlapping ASD/ID/
DD-associated genes from Satterstrom et al. (2020) and DDD Study (2017). 
Table 9  Overlap of Australian Autism Biobank (AAB) phenotypes with 
the Simons Simplex Collection (SSC) and Simons Foundation Powering 
Autism Research for Knowledge (SPARK).
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Schedule-2; ADOS-G: Autism Diagnostic Observation Schedule-G; Autism CRC 
: Cooperative Research Centre for Living with Autism; ASD: Autism spectrum 
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disorder. Predominantly used to denote the experimental group diagnosed 
with ASD, or queried for the condition; CSHQ: Children’s Sleep Habits Ques-
tionnaire; CNV: Copy-number variant; GWAS: Genome-wide association study; 
ID: Intellectual disability; IQ: Intelligence quotient; MSEL: Mullen Scales of Early 
Learning; PGS: Polygenic risk score; SIB: Sibling group; SNP: Single nucleotide 
polymorphism; SRS: Social Responsiveness Scale; SSP-2: Short Sensory Profile, 
version 2; UNR: Unrelated group without an ASD diagnosis; WASI: Wechsler 
Abbreviated Scale of Intelligence, 2nd edition; WISC-IV: Wechsler Intelligence 
Scale for Children, 4th edition.
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